Trial Profile

A Phase 2, Randomized, Open-Label Study of Bosutinib Administered in Combination With Exemestane Versus Exemestane Alone as Second Line Therapy in Postmenopausal Women With Locally Advanced or Metastatic ER+/PgR+/ErbB2- Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Oct 2021 This trial has been completed in Spain and France (End Date: 31 May 2010), according to European Clinical Trials Database record.
15 Feb 2012 Additional locations added as reported by Clinical Trials Registry - India record.
29 Aug 2011 Planned end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com